Next Generation Immuno-Oncology

Syntab Therapeutics

The human body has a powerful natural defense system. At Syntab Therapeutics, we harness the potential of the innate immune system—the body's first line of immune defense—to fight cancer. Our innovative approach is designed to direct the patient’s own immune system against cancer cells using small, fully synthetic molecules called Immune System Engagers (ISErs).

By combining targeted tumor recognition with innate immune activation, ISErs aim to enable a precise and effective immune response against cancer. ISErs combine targeted binding, immune activation and the advantages of synthetic molecular design. Their small molecular architecture offers the potential for efficient tissue penetration, while their modular design supports the development of multivalent and multispecific molecules. Manufactured through chemical synthesis, ISErs also offer the potential for scalable, cost-efficient production and streamlined molecular optimization.

Through this approach, Syntab Therapeutics aims to establish a new generation of immunotherapies that harness innate immunity to fight cancer.

Modular approach offers multiple options

The ISErs combine highly selective binders for recognizing cancer cells and immune activators in one small peptide of 5 to 10 kD. Such molecules are highly versatile in design, relatively easy to synthesize, and can be tailored to target specific types of cancer. An ISEr can have up to four different binder arms that target multiple cancer-specific cell markers, in addition to the immune activators. Due to their structural flexibility, ISErs can be chemically synthesized within just a few days and at low cost.

ISEr: A Targeted Approach to Cancer Immunotherapy

The platform`s patented lead compound, ISEr-X9 has already demonstrated successful in-vitro and in-vivo proof of concept. In a mouse model of Triple-Negative Breast Cancer (TNBC) treatment with ISEr-X9 was associated with substantial tumor necrosis—the death of tumor tissue. Additional analyses identified changes in neutrophil-associated proteins and inflammatory signalling, providing evidence of an immune response following treatment. Studies using human breast cancer tissue explants also revealed changes in inflammatory and tissue-remodelling markers. Syntab Therapeutics is advancing ISEr-X9 towards its planned first-in-human study while continuing to expand its ISEr platform to address a broader range of hard-to-treat tumor types.